IP Library Granted Patent US 8,487,096
Granted Patent B2
US 8,487,096 · App. 13/019,718 · Granted Jul 16, 2013

Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors

Inventors: Jincong Zhuo (Garnet Valley, PA); Chunhong He (Chadds Ford, PA); Wenqing Yao (Chadds Ford, PA)
Assignee: Incyte Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,487,096
App. No.
13/019,718
Granted
Jul 16, 2013
Kind
B2
Abstract

The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.

Claims (11)

1. A compound which is:

2-fluoro-N-[(2R)-2-hydroxypropyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; or

2-chloro-N-[(1S)-1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;

or a pharmaceutically acceptable salt of any of the aforementioned.

2. The compound 2-fluoro-N-[(2R)-2-hydroxypropyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, or a pharmaceutically acceptable salt thereof.

3. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

4. A method of treating a disease in a patient, wherein said disease is associated with dysregulation of the HGF/c-MET signaling pathway, comprising administering to said patient a therapeutically effective amount of a compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein said disease is breast cancer.

5. A method of treating breast cancer in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 2 , or a pharmaceutically acceptable salt thereof.

6. The compound 2-chloro-N-[(1S)-1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, or a pharmaceutically acceptable salt thereof.

7. A method of treating a disease in a patient, wherein said disease is associated with dysregulation of the HGF/c-MET signaling pathway, comprising administering to said patient a therapeutically effective amount of a compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein said disease is breast cancer.

8. A method of treating breast cancer in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 6 , or a pharmaceutically acceptable salt thereof.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY INFORMATION PREVIOUSLY RECORDED ON REEL 035920 FRAME 0576. ASSIGNOR(S) HEREBY CONFIRMS THE RECEIVING PARTY NAME SHOULD BE RECORDED AS TWO PARTIES. Recorded Jul 2, 2015
From: INCYTE CORPORATION
To: INCYTE HOLDINGS CORPORATION; INCYTE CORPORATION
Reel/Frame 036054/0740 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2015
From: INCYTE CORPORATION
To: INCYTE HOLDINGS CORPORATION AND INCYTE CORPORATION
Reel/Frame 035920/0576 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2011
From: ZHUO, JINCONG; HE, CHUNHONG; YAO, WENQING
To: INCYTE CORPORATION
Reel/Frame 026317/0023 →
Continuity (2)
Provisional Application 61300946 · Feb 3, 2010
Related Publication 20110212967A1 · Sep 1, 2011